Market Overview

UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails

Share:
Related
Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation
Harvard Explains The Health Effects Of Medical And Recreational Use Of Marijuana
Are We At The Point Of Maximum Financial Risk For Bonds? (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.

In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”

AbbVie closed on Monday at $53.37.

Latest Ratings for ABBV

DateFirmActionFromTo
Jun 2016BMO CapitalDowngradesOutperformMarket Perform
Jun 2016Morgan StanleyDowngradesOverweightEqual-weight
Jun 2016Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!